Alopecia

Alopecia areata treatment advances with targeted therapies, improving patient outcomes and access while addressing the emotional impact of hair loss.

Happy Head's StrandIQ system revolutionizes hair loss treatment with personalized genetic analysis, enhancing hair growth and scalp health for individuals.

Explore the latest breakthroughs in treatment and research during Hair Loss Awareness Month, enhancing understanding and patient care for hair loss disorders.

Research highlights that educational videos on standardized clinical photography protocols significantly lead to better management and treatment outcomes for patients with alopecia.

Key regulatory milestones for MAL-838, a novel sCD83-based, hormone-free hair growth ingredient, are paving the way for the market launch of a microbiome-friendly 8T3 product line.

In this exclusive Q&A, Alan J. Bauman, MD, shares expert insights on innovative hair loss treatments, early intervention strategies, and the future of alopecia care.

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.

At Elevate-Derm Summer, Buchi Neita, MCMSc, PA-C, discussed enhancing dermatologic care for patients with skin of color by recognizing characteristics in common conditions and offered strategies to build rapport with patients.

Nektar Therapeutics advances alopecia areata treatment with FDA's Fast Track designation for rezpegaldesleukin, targeting immune modulation in chronic hair loss.

Amy Spizuoco, DO, FAOCD, shares groundbreaking insights on alopecia treatments and emerging STIs at this year's Elevate-Derm Summer Conference, enhancing patient care.

Tina Bhutani, MD, shares vital insights on psoriasis management, sleep's role in dermatology, and new alopecia areata treatments at Elevate-Derm Summer 2025.

A first-of-its-kind study reveals artificial intelligence (AI)-driven insights on hair loss trends, highlighting the impact of genetics, hormones, and COVID-19 on alopecia.

Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the US, offering a new treatment for adults with severe alopecia areata.

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

From JAK inhibitors to trichoscopy and contact allergy clues, experts at SDPA 2025 shared their top clinical pearls for managing alopecia and hair loss.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.